T. Nitro-oleic acid protects against adriamycin-induced nephropathy in mice.
-Adriamycin (ADR) administration in susceptible rodents such as the BALB/c mouse strain produces injury to the glomerulus mimicking human focal glomerular sclerosis. The goal of the present study was to use this model to investigate antiproteinuric action of nitro-oleic acid (OA-NO 2), a nitric oxide-derived endogenous lipid product, which has exhibited multiple attractive signaling properties particularly in the kidney. BALB/c mice were pretreated for 2 days with OA-NO2 at 5 mg·kg Ϫ1 ·day Ϫ1 via an osmotic minipump, followed by a single injection of vehicle or adriamycin (10 mg/kg) via the tail vein. Albuminuria and renal function were analyzed at 1 wk post-ADR treatment. ADR mice developed prominent albuminuria, hypoalbuminemia, hyperlipidemia, and severe ascites. In contrast, the symptoms of nephrotic syndrome were greatly improved by OA-NO2 treatment. In parallel, plasma creatinine and plasma urea nitrogen were elevated in the ADR group, and the severity was less in the ADRϩOA-NO 2 group. OA-NO2 attenuates ADR-induced glomerulosclerosis, podocyte loss, and tubulointerstitial fibrosis. Indices of oxidative stress, including plasma and urinary thiobarbituric acidreactive substances and renal expression of NAD(P)H oxidase p47 phox and gp91 phox , and inflammation, including renal expression of TNF-␣, IL-1␤, and MCP-1 in response to ADR, were all similarly suppressed. Together, these findings suggest that OA-NO 2 exerts renoprotective action against ADR nephropathy likely via its anti-inflammatory and antioxidant properties. adriamycin; albuminuria; glomerulosclerosis; OA-NO 2; oxidative stress PROTEINURIA IS AN EARLY AND predominant pathological feature of a wide variety of primary glomerular disease, and it is not only a marker for the progression and prognosis of kidney injury but also an important pathogenic mediator that causes subsequent oxidant stress, inflammatory, and fibrotic responses in the kidney, finally leading to end-stage renal disease. Podocytes are one of the principal components of the glomerular filtration barrier and play a crucial role in the regulation of glomerular function, and podocyte injury is one of the major causes leading to defective glomerular filtration, resulting in proteinuria (20, 25, 32) . Therefore, protection of podocytes in proteinuric kidney disorders should be a major strategy to prevent the worsening of renal disease, but drugs clinically available for that goal are not very effective.
Adriamycin (ADR) is an anthracycline antibiotic used widely in solid and hematopoietic malignancy therapies as one of the simplest and most effective chemotherapeutic agents. It can cause podocyte foot process effacement and increase glomerular permeability, leading to proteinuria (8, 11, 17) . The mechanism involved in ADR nephropathy is still incompletely understood. Among many possible pathogenic factors, oxygen free radicals and inflammation are thought to play a role (21, 28) .
OA-NO 2 is an electrophilic nitroalkenyl fatty acid with several attractive signaling properties. It is detected in healthy human blood, reaching ϳ0.6 M (3), and increased production is demonstrated during inflammatory and metabolic stress (4, 24) . The signaling pathway transducing the action of OA-NO 2 appears to be complex and remains to be defined particularly under pathophysiological condition in vivo. In vitro studies suggest that OA-NO 2 may signal through activation of peroxisome proliferator-activated receptors (PPARs) (3), S-alkylation of critical thiols of Keap-1, and subsequent activation of Nrf2 (4, 16, 27) , covalent modification of the p65 subunit of NF-B, and suppression of its activity (9) . A series of our previous studies demonstrates that OA-NO 2 is protective against kidney injury induced by ischemia-reperfusion and endotoxin-induced sepsis, and in obese Zucker rats (18, 29 -30) . The present study was undertaken to examine the potential therapeutic action and mechanism of OA-NO 2 in a murine model of ADR nephropathy.
MATERIALS AND METHODS
Materials. OA-NO2 was synthesized and purified as described previously (3) . ADR (doxorubicin HCl) was purchased from Bedford Laboratories. All other reagents were purchased from Sigma-Aldrich unless otherwise specified.
Animals and treatments. Male BALB/c mice were purchased from the Jackson Laboratories (Bar Harbor, ME). Mice were maintained in a temperature-controlled barrier facility with a 12:12-h light-dark cycle and were given free access to standard laboratory chow and tap water. Mice were randomized into three groups: group 1: control, group 2: ADR, and group 3: ADRϩOA-NO 2. In group 3, OA-NO2 (dissolved in ethanol) was administered at 5 mg·kg Ϫ1 ·day Ϫ1 via a subcutaneously implanted osmotic minipump, and vehicle (ethanol) was given to the other two groups. This dose was chosen based a previous study (36) . After 2 days of pretreatment with OA-NO 2, groups 2 and 3 received a single tail vein injection of ADR at 10 mg/kg. Group 1 received a single tail vein injection of saline. Twenty-four-hour urine was collected using metabolic cages. Seven days after ADR treatment, all mice were euthanized and the kidneys were immediately harvested for gene expression or histological analyses. All protocols employing mice were conducted in accordance with the principles and guidance of the University of Utah Institutional Animal Care and Committee.
Measurement of biochemical parameters. Urine samples were centrifuged for 5 min at 10,000 rpm. Blood samples from anesthetized mice were collected by puncturing the vena cava using a 1-ml insulin syringe containing 50 l of 1 mM EDTA in the absence of protease inhibitors. Urine and plasma albumin were determined using a murine microalbuminuria enzyme-linked immunosorbent assay kit (1011, Exocell). The plasma triglyceride level was determined using a LabAssay Triglyceride ELISA Kit (290-63701, Wako). Urine and plasma levels of urea were measured with a Urea Nitrogen Direct Kit (0580-250, Stanbio Laboratory), and urine and plasma levels of creatinine were measured using a Creatinine Liquicolor Kit (0420-250, Stanbio Laboratory).
Morphological studies. Under anesthesia, kidneys are removed and fixed with 4% paraformaldehyde. The tissues were subsequently embedded in paraffin, and 4-m sections were cut and stained with periodic acid-Schiff (PAS). Glomerular sclerosis was assessed as follows using a semiquantitative score previously described (30 -32) : grade 0, normal appearance; grade I, involvement of up to 25% of the glomerulus; grade II, involvement of 25-50% of the glomerulus; grade III, involvement of 50 -75% of the glomerulus; and grade IV, involvement of 75-100% of the glomerulus. A glomerulosclerosis index (GSI) was calculated by multiplying the number of glomeruli with a sclerosis score of I by one, the number with a score of II by two, III by three, and IV by four. These values were summed and divided by the number of glomeruli assessed, including those with a sclerosis score of zero. The GSI for each kidney specimen was a sum of the points from 30 glomeruli. Tubulointerstitial injury (defined as tubular atrophy, dilatation, thickening of the basement membrane, protein cast) was assessed by semiquantitative analysis (33, 34) . Thirty cortical fields from each animal were examined at ϫ200 magnification and graded according to a scale of 0 -4: 0, no tubulointerstitial injury; 1, Ͻ25% of the tubulointerstitium injured; 2, 25-50% of the tubulointerstitium injured; 3, 51-75% of the tubulointerstitium injured; and 4, 76 -100% of the tubulointerstitium injured. All sections were examined in a blind manner.
Immunohistochemistry. Immunohistochemical staining was performed as previously described (15) . Anti-WT1 antibody was purchased from Dako (Mob437, Dako).
Quantitative RT-PCR. Total RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA), and first-strand cDNAs were synthesized from 2 g of total RNA in a 20-ml reaction using SuperScript (Invitrogen). The first-strand cDNAs served as the template for quantitative (q) PCR performed in the Applied Biosystems 7900 Real Time PCR System using SYBR green PCR reagent (Applied Biosystems, Foster City, CA). The amplification was carried out for 40 cycles with conditions of 15-s denaturation at 95°C. The sequence of oligonucleotides used for qPCR (RT-PCR) is listed as follows: GAPDH sense: 5=-GTC TTCACTACCATGGAGAAGG-3= and antisense: 5=-TCATGGATGACCTTGGCC AG-3=; fibronectin (FN) sense: 5=-CGTGGAGCAAGAAGGACAA-3= and antisense: 5=-GT-GAGTCTGCGGTTGGTAAA-3=; smooth muscle actin (SMA)-␣ sense: 5=-CCCTGAAGAGCATCC GACA-3= and antisense: 5=-CCA-GAGTCCAGCACAATACC-3=; transforming growth factor (TGF)-␤ sense: 5=-TAC GCCTGAGTGGCTGTCTT-3= and antisense: 5=-CGTGGAGTTTGTTATCTTTGCT-3=; zonula occludens (ZO)-1 sense: 5=-GCGCGGAGAGAGACAAGA-3= and antisense: 5=-CTG-GCCCTC CTTTTAACACA-3=; p47 phox sense: 5=-CACTCCCTTT-GCTTCCATCT-3= and antisense: 5=-ATGTTGCTATCCCAGCC-AGT-3=; gp91 phox sense: 5=-CCGTATTGT GGGAGACTGGA-3= and antisense: 5=-CTTGAGAATGGAGGCAAAGG-3=; desmin sense: 5=-GTGGATGCAGCCACTCTAGC-3= and antisense: 5=-TTAGC-CGCGATG GTCCATAC-3; TNF-␣ sense: 5=-TCCCCAAAGGGAT-GAGAAG-3= and antisense: 5=-CACTTGGTGGTTTGCTACGA-3=; IL-1␤ sense: 5=-ACTGTGAAATGCCACTTT TG-3= and antisense: 5=-TGTTGATGTGCTGCTGTGAG-3=; MCP-1 sense: 5=-GCT CT-CTCTTCCTCCACCAC-3= and antisense: 5=-ACAGCTTCTTTGG-GACACCT-3=; and collagen type III sense: 5=-AGGCAACAGTG-GTTCTCCTG-3= and reverse 5=-GAC CTCGTGCTCCAGTTAGC-3=.
Immunoblotting. The kidney lysates were stored at Ϫ80°C until assayed. Protein concentrations were determined using Coomassie reagent. An equal amount of the whole tissue protein was denatured at 100°C for 10 min, separated by SDS-PAGE, and transferred onto nitrocellulose membranes. The blots were blocked overnight with 5% nonfat dry milk in Tris-buffered saline (TBS), followed by incubation for 1 h with a primary antibody. The blots were washed with TBS followed by incubation with a horseradish peroxidase-conjugated secondary antibody. Immune complexes were detected using ECL methods. The immunoreactive bands were quantified using the Gel and Graph Digitizing System (Silk Scientific, Tustin, CA).
Measurement of thiobarbituric acid-reactive substances. The measurement of thiobarbituric acid-reactive substances (TBARS) in the mouse kidney was based on the formation of malondialdehyde (MDA) by using a commercially available TBARS Assay kit (10009055, Cayman Chemical) according to the manufacturer's instructions.
Statistical analysis. All values are represented as means Ϯ SE. Data were analyzed using an unpaired t-test or ANOVA followed by a Bonferroni posttest. Differences were considered to be significant when P Ͻ 0.05. 2 attenuates albuminuria and renal dysfunction. BALB/c mice were administered vehicle, ADR, or ADR in combination with OA-NO 2 ; OA-NO 2 was delivered via an osmotic minipump 2 days before ADR injection. At day 5 after ADR injection, albuminuria was most evident in the ADR group (508.89 Ϯ 48.52 g/24 h) compared with the control group (33.39 Ϯ 3.50 g/24 h) and was attenuated in the ADRϩOA-NO 2 group (342.40 Ϯ 33.26 g/24 h). (Fig. 1) . These changes were observed at day 3 and maintained at day 7. At day 7, plasma albumin was significantly reduced in the ADR group (0.28 Ϯ 0.08 g/dl) compared with the control group (1.01 Ϯ 0.15 g/dl) and was significantly restored in the ADRϩOA-NO 2 group; the decrease in plasma albumin levels was significantly attenuated (0.58 Ϯ 0.13 g/dl) ( Fig. 2A) . Ninety percent of ADR mice had severe ascites at death, in contrast to only 20% of ADRϩOA-NO 2 mice, who had mild ascites (Fig. 2B) .
RESULTS

OA-NO
ADR mice developed severe hyperlipidemia (plasma triglyceride: 396.18 Ϯ 70.94 mg/dl) that was less in the ADRϩOA-NO 2 group (plasma triglyceride: 212.70 Ϯ 39.22 mg/dl) (Fig. 3A) . Plasma creatinine and blood urea nitrogen (BUN) were determined to reflect renal function. ADR mice had elevated plasma creatinine and BUN, both of which were significantly attenuated in the ADRϩOA-NO 2 group (Fig. 3, B and C) . OA-NO 2 attenuates glomerular injury and renal fibrosis. To correlate the reduction of albuminuria with glomerular structure, the effect of drug treatments on glomerulosclerosis was assessed by PAS staining. Being consistent with the data on albuminuria, results from the ADR mice showed marked glomerulosclerosis as evidenced by mesangial expansion and increased accumulation of extracellular matrix (ECM) in the mesangium (Fig. 4A) . A semiquantitative glomerulosclerotic index of kidney sections confirmed the histological data. The ADR mice showed the highest score, and OA-NO 2 treatment led to a marked reduction in the index (P Ͻ 0.05) (Fig. 4B) .
Because podocyte injury is an early and predominant pathological feature of the ADR model, we examined expression of a number of podocyte markers. WT1 is a pivotal transcription factor that is essential for the maintenance of the differentiated features of adult podocytes (35, 36) . As illustrated in Fig. 5, A and B, immunoblotting revealed a marked reduction of WT1 after ADR injury compared with controls; OA-NO 2 pretreatment prevented the downregulation of WT1 in the ADR mice (P Ͻ 0.05). The number of podocytes was semiquantitively analyzed by immunohistochemical analysis of WT-1. The number of WT1-positive cells was reduced in the ADR group and was partially restored in the ADRϩOA-NO 2 group (Fig. 5,  C and D) . qRT-PCR was performed to examine mRNA expression of ZO-1 and desmin. Renal ZO-1 mRNA exhibited a trend of reduction in the ADR group compared with the control group and a significant elevation in the ADRϩOA-NO 2 group (Fig. 5E ). Desmin mRNA was upregulated in the ADR mice, and treatment with OA-NO 2 prevented this increase (Fig. 5F ).
We further examined renal fibrosis by determining the expression of ␣-SMA and FN and TGF-␤ in the kidney. As shown in Fig. 6 , ADR mice showed marked increases in ␣-SMA and FN expression at the mRNA level relative to the control by real-time PCR (Fig. 6, A and B) , and Western blotting revealed marked upregulation of ␣-SMA and FN (Fig.  6, C and D) . The densitometric values of these two proteins are shown in Fig. 6 , E and F. OA-NO 2 treatment prevented the upregulation of ␣-SMA and FN in the ADR mice (P Ͻ 0.05). In addition, the mRNA expression of several other fibrosis/ sclerosis-related genes in the kidney was upregulated in the ADR mice, including TGF-␤ (Fig. 6G ) and collagen III (Fig.  6H) . OA-NO 2 treatment induced a dramatic suppression of these genes in the kidney (P Ͻ 0.05). These data are consistent with the antisclerotic effect of OA-NO 2 treatment.
OA-NO 2 hampers renal oxidative stress. Among many possible pathogenic factors, oxidative stress has emerged as an important pathogenic factor in the development of ADR nephropathy. To investigate whether OA-NO 2 had an antioxidative effect on ADR mice, we analyzed plasma and urinary levels of TBARS, a reliable product of lipid oxidation. As a result, the ADR group showed a marked increase in plasma (Fig. 7A), urinary (Fig. 7B) , and kidney ( compared with the control group. Treatment with OA-NO 2 markedly attenuated the ADR-induced increase in plasma and urinary TBARS compared with ADR mice (Fig. 7, A and B) .
There was a trend of reduction of TBARS levels in response to OA-NO2 treatment, but this did not reach a statistical significance. NAD(P)H oxidase is an important source of reactive oxygen species (ROS) generation in various pathological conditions. We therefore examined renal expression of major subunits of NAD(P)H oxidase. As shown in Fig. 8, A and B, renal mRNA expression of p47 phox and gp91 phox was significantly increased in ADR mice compared with the control group, and the increase was less in the ADRϩOA-NO 2 group (P Ͻ 0.05). The change in gp91 phox was further confirmed at the protein level (P Ͻ 0.01; Fig. 8, C and D) .
OA-NO 2 hampers renal inflammation. ADR induces a proinflammatory response in the kidney, releasing cytokines and chemokines responsible for subsequent kidney injury. To examine whether OA-NO 2 could reduce inflammation, we performed qRT-PCR analysis of TNF-␣, IL-1␤, and MCP-1. The renal expression of these proinflammatory mediators was in induced in parallel in ADR mice, and the inductions were all suppressed by OA-NO 2 (Fig. 9, A-C) .
DISCUSSION
OA-NO 2 is a recently identified as an endogenous signaling molecule capable of activating PPARs, inhibiting NF-B, and releasing NO. A series of studies from our group demonstrated that OA-NO 2 exerts renoprotective action in animal models of kidney injury induced by ischemia-reperfusion, endotoxemia, and metabolic syndrome. Of particular note, OA-NO 2 effectively lowered proteinuria in obese Zucker rats, suggesting a possible protective action of OA-NO 2 against glomerular disease (29) . ADR-induced kidney damage is one of the few exciting murine models of acquired glomerulonephropathy, in which progressive renal damage leads to terminal renal failure (10, 12, 19, 31, 35) . Despite the incomplete understanding of the underlying mechanism, ADR in susceptible genetic backgrounds induces pathological glomerular changes similar to human focal glomerular sclerosis (10) . In the present paper, we use this model to explore the therapeutic potential and mechanism of OA-NO 2 in the management of glomerular disease.
In the BALB/c background, ADR administration induced the typical nephritic syndrome, characterized by severe albuminuria, hypoalbuminemia, hyperlipidemia, and ascites. As a major mechanism of these symptoms, ADR can directly injure the podocytes, resulting in proteinuria and glomerular sclerosis. Greater proteinuria leads to the lowering of plasma albumin concentration and plasma osmolality, which sequentially reduce GFR via a prerenal mechanism. Increasing evidence suggests that proteinuria alone can cause kidney injury. Hyperlipidemia is one of the major features of ADR nephropathy (6, 19) . Increasing evidence suggests that hyperlipidemia and renal lipotoxicity are important pathogenic factors in kidney damage (5, 23) and may contribute to the development and the progression of ADR nephropathy. Administration of OA-NO 2 significantly improved all the symptoms mentioned above as well as renal function. The major mechanism of the protective action of OA-NO 2 in this model is likely through the protection of podocytes. Podocytes play a crucial role in the regulation of glomerular function. Injury to podocytes can disrupt the structural and functional integrity of the slit diaphragm, leading to proteinuria. In this model, podocyte injury was an early-occurring event. After 7 days of ADR injection, WT1 protein was markedly downregulated, and OA-NO 2 was able to significantly preserve its expression. We also examined the mRNA levels of the epithelial maker ZO-1 and the mesenchymal marker desmin. OA-NO 2 reversed the reduction of ZO-1 and increase in desmin. Consistent with these results, histologically OA-NO 2 treatment ameliorated ADR-induced glomerulosclerosis, alleviated the accumulation of mesangial matrix, attenuated the prominent tubular dilation, reduced the intraluminal protein casts, and improved the narrow Bowman's capsule. It is somewhat puzzling that on day 7 of OA-NO2 treatment, despite the marked improvement of kidney injury, the attenuation of albuminuria was relatively modest (the P value is still Ͻ0.05) compared with the two other early time points. The reason for this phenomenon is unclear. One possibility is that severe hypoabuminemia after 7 days of ADR treatment had reduced the further leakage of albumin from the damaged glomeruli and therefore had masked the therapeutic effect of OA-NO 2 .
Oxidative stress has emerged as an important pathogenic factor in the development of ADR nephropathy (11, 17, (33) (34) . In the present study, we showed that pretreatment with OA-NO 2 ameliorated albuminuria concomitantly with a reduction of TBARS levels in both urine and plasma. The NADPH oxidase system is a major superoxide-generating system contributing to ROS generation in chronic kidney disease, including ADR nephropathy (11) . We found that OA-NO 2 significantly attenuated ADR-induced upregulation of NADPH oxidase subunits gp91 phox and p47 phox at both the mRNA and protein levels; gp91 phox and p47 phox are of particular importance as the former contains the catalytic domain and the latter is necessary for cytosolic subunit translocation and for initiation of NADPH oxidase assembly in the kidney. These results suggest that the antioxidant property of OA-NO 2 via suppressing NADPH oxidase expression may in part account for the renoprotective action of this compound.
Inflammation is an important component of the pathophysiology of ADR nephropathy (7, 22, 26, 33) . Histological assessment of the kidneys of ADR-treated mice shows tubulointerstitial inflammation with infiltration of T and B lymphocytes and macrophages. While studies in severe combined immunodeficient (SCID) mice shows that ADR nephropathy does not require lymphocytes, deletion and reconstitution studies demonstrate a pivotal role of macrophages in the disease process (1, 8, 14) . Our results revealed excessive renal production of proinflammatory cytokines TNF-␣, IL-1␤, and MCP-1 in the early stage of ADR nephropathy. Administration of OA-NO 2 significantly inhibited the induction of the proinflammatory cytokines. In support of this finding is the observation that in cultured RAW264.7 cells, a murine macrophage cell line, OA-NO 2 attenuates the endotoxin-elicited inflammatory response via diverse mechanisms involving activation of mitogen-activated protein kinase phosphatase 1 (13) and nitroalkylation of NF-B p65 (9, 11) . Moreover, our previous study demonstrated anti-inflammatory and renoprotective actions of OA-NO 2 in endotoxin-induced endotoxemia in mice (30) .
In summary, the present study demonstrates that OA-NO 2 protects against ADR nephropathy possibly through the inhibition of oxidative stress and inflammation. These findings suggest the therapeutic potential of OA-NO 2 for management of human glomerular disease, such as focal segmental glomerulosclerosis. Our study will provide a basis for the rational design of such clinical trials.
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